Viviane Hess
Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications - the PLEURA study.
Dittrich T, Aujesky M, Rudin S, Zietz A, Wagner B, Polymeris A, Altersberger V, Sinnecker T, Gensicke H, Engelter S, Lyrer P, Hess V, Sutter R, Nickel C, Bonati L, Fischer U, Psychogios M, Katan M, De Marchis G. Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications - the PLEURA study. Eur Stroke J 2023; 8:549-556.
Jan 23, 2023Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications - the PLEURA study.
Jan 23, 2023Eur Stroke J 2023; 8:549-556
Dittrich Tolga, Aujesky Mara, Rudin Salome, Zietz Annaelle, Wagner Benjamin, Polymeris Alexandros A, Altersberger Valerian L, Sinnecker Tim, Gensicke Henrik, Engelter Stefan T, Lyrer Philippe A, Hess Viviane, Sutter Raoul, Nickel Christian H, Bonati Leo H, Fischer Urs, Psychogios Marios-Nikos, Katan Mira, De Marchis Gian Marco
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.
Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner A, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller T. Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. Eur J Cancer 2022; 177:186-193.
Oct 5, 2022Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.
Oct 5, 2022Eur J Cancer 2022; 177:186-193
Panje Cédric, Hayoz Stefanie, Eisterer Wolfgang, Hess Viviane, Thuss-Patience Peter, Schacher Sabina, Dürr Donat, Wagner Anna Dorothea, Girschikofsky Michael, Eboulet Eric I, Stahl Michael, Ruhstaller Thomas
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
Apr 13, 2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Apr 13, 2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2012; 23:632-9.
Aug 24, 2012Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
Aug 24, 2012Eur Radiol 2012; 23:632-9
Schmidt Noemi, Hess Viviane, Zumbrunn Thomas, Rothermundt Christian, Bongartz Georg, Potthast Silke
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
Jan 4, 2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Jan 4, 2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116.
Feb 7, 2009Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Feb 7, 2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116
Ribi Karin, Pestalozzi Bernhard, Lombriser Norbert, Borner Markus, von Moos Roger, Moosmann Peter, Hess Viviane, Roth Arnaud, Honegger Hanspeter, Schuller Jan C, Köberle Dieter, Ruhstaller Thomas
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Hess V, Scheithauer W, Figer A, Saletti P, Bajetta E, Ruhstaller T, Bodoky G, Dietrich D, Grawe P, Glimelius B, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. The lancet oncology 2008; 9:132-8.
Feb 1, 2008CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Feb 1, 2008The lancet oncology 2008; 9:132-8
Hess Viviane, Scheithauer Werner, Figer Arie, Saletti Piercarlo, Bajetta Emilio, Ruhstaller Thomas, Bodoky György, Dietrich Daniel, Grawe Philipp, Glimelius Bengt, Herrmann Richard